News >

Real-World Findings Support Nivolumab Use in HNSCC

Angelica Welch
Published: Wednesday, Dec 12, 2018

Nivolumab (Opdivo) demonstrated durable response and overall survival (OS) rates in a real-world analysis of patients with platinum-refractory, recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).1 These findings support the CheckMate-141 safety and activity data in this population, which historically has had a poor prognosis.

“These promising results encourage the use of nivolumab in this population, but further follow-up and more mature data are still needed,” concluded Bruixola and colleagues.

References

  1. Bruixola G, Caballero Daroqui J, Cunquero Tomas AJ, et al. Safety and efficacy of nivolumab (nivo) in platinum-refractory recurrent/metastatic head and neck squamous cell (PR R/M HNSCC) patients (pts): real-life experience. Ann Oncol. 2018;29(Suppl 8):viii372-viii399. doi: 10.1158/1538-7445.AM2018-CT116.
  2. Ferris RL, Blumenschein GR, Fayette J, et al. Nivolumab (Nivo) vs investigator’s choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141. In: Proceedings from the American Association for Cancer Research Annual Meeting 2018; April 14-18, 2018; Chicago, Illinois. Abstract CT116. doi: 10.1158/1538-7445.AM2018-CT116.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication
x